Genocea Biosciences (NASDAQ:GNCA) inks a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. (OTCPK:SGIOY) to develop a novel herpes simplex virus type 2 (HSV-2) vaccine.
Under the terms of the deal, Shionogi will pay
Genocea $2M for the exclusive option to evaluate the latter’s HSV-2
antigens from its defunct GEN-003 program and negotiate a license
agreement prior to expiration of the MTA.
If Shionogi exercises its option, GNCA will be eligible for an upfront payment, milestones and tiered royalties on net sales.
https://seekingalpha.com/news/3575858-genocea-teams-up-shionogi-to-develop-herpes-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.